Positive results from Roche‘s Phase III evERA research, which showed that the investigational medication giredestrant, when taken with everolimus, significantly improves outcomes for patients with advanced hormone-sensitive breast cancer, were announced today. This is a significant advancement for the treatment of cancer. For patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally progressed, or metastatic breast cancer, the all-oral regimen demonstrated a significant improvement in progression-free survival.
Both of its co-primary objectives were fulfilled by the research, which compared the giredestrant combination to standard-of-care endocrine treatment plus everolimus. It demonstrated a statistically significant and clinically significant improvement in progression-free survival (PFS) in a subgroup of patients with the ESR1 mutation as well as in the entire research cohort. Although data on overall survival (OS) is still developing, a definite upward trend was noted.
Read More: Roche’s Itovebi Shows Significant Survival Benefit in HR-positive Advanced Breast Cancer
As the first successful head-to-head Phase III study to assess an all-oral selective oestrogen receptor degrader (SERD) regimen versus a standard-of-care combo medication, this trial represents a significant accomplishment.
Approximately 70% of all cases of breast cancer are ER-positive. Resistance to endocrine therapy is nevertheless a significant obstacle in spite of advancements, raising the chance of disease development and producing unfavorable results. By focusing on two distinct signaling pathways, the combination of giredestrant and everolimus is intended to get around this, possibly enhancing patient outcomes and providing a fresh line of defense. Another major benefit of the medication is that it is entirely oral, which may reduce the burden on a person’s day-to-day activities by doing away with the need for injections.
Read More: A novel immunotherapy combination for breast cancer and melanoma
These results show that the giredestrant combination provided a meaningful benefit for ER-positive breast cancer patients whose disease has progressed following treatment with a CDK inhibitor,
We look forward to discussing these results with regulatory authorities with the goal of making this giredestrant-based regimen available to many people with advanced ER-positive breast cancer.
Levi Garraway
Understanding the evERA Study and Giredestrant
Patients with ER-positive, HER2-negative breast cancer who had previously had endocrine therapy and a CDK 4/6 inhibitor were recruited for the evERA Breast Cancer study (NCT05306340), a Phase III, randomized, open-label experiment. Investigator-assessed PFS in the ESR1-mutated and intention-to-treat groups served as the study’s co-primary objectives. Safety, objective response rate, and overall survival were secondary goals. No new safety signals were noticed, and the giredestrant combination’s safety profile aligned with the established profiles of the individual treatments.
Giredestrant is an oral, next-generation, complete antagonist and selective oestrogen receptor degrader (SERD) that is currently under development. It functions by preventing the oestrogen receptor, a major factor in the proliferation of cancer cells in ER-positive breast cancer, from binding to oestrogen. By causing the receptor to break down (degrade), this action effectively stops or slows the development of cancer cells.
Last Modified:
Graduated from the University of Kerala'20 with B.Sc. Botany & Biotechnology. Post-graduation in Biotechnology from the University of Kerala'22. Internship experience in Cancer Research.
